Development of an in vivo cleavable donor plasmid for targeted transgene integration by CRISPR-Cas9 and CRISPR-Cas12a

被引:4
|
作者
Ishibashi, Riki [1 ,2 ]
Maki, Ritsuko [1 ]
Kitano, Satsuki [3 ]
Miyachi, Hitoshi [3 ]
Toyoshima, Fumiko [1 ,2 ]
机构
[1] Kyoto Univ, Inst Life & Med Sci, Dept Biosyst Sci, Sakyo Ku, Kyoto 6068507, Japan
[2] Kyoto Univ, Grad Sch Biostudies, Dept Mammalian Regulatory Networks, Sakyo Ku, Kyoto 6068502, Japan
[3] Kyoto Univ, Inst Life & Med Sci, Reprod Engn Team, Sakyo Ku, Kyoto 6068507, Japan
关键词
ONE-STEP GENERATION; EFFICIENT GENERATION; PROGENITOR CELLS; MICE; SYSTEMS; MOUSE; GENE; ENDONUCLEASE; CRISPR/CAS9; REPORTER;
D O I
10.1038/s41598-022-22639-6
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The CRISPR-Cas system is widely used for genome editing of cultured cells and organisms. The discovery of a new single RNA-guided endonuclease, CRISPR-Cas12a, in addition to the conventional CRISPR-Cas9 has broadened the number of editable target sites on the genome. Here, we developed an in vivo cleavable donor plasmid for precise targeted knock-in of external DNA by both Cas9 and Cas12a. This plasmid, named pCriMGET_9-12a (plasmid of synthetic CRISPR-coded RNA target sequence-equipped donor plasmid-mediated gene targeting via Cas9 and Cas12a), comprises the protospacer-adjacent motif sequences of Cas9 and Cas12a at the side of an off-target free synthetic CRISPR-coded RNA target sequence and a multiple cloning site for donor cassette insertion. pCriMGET_9-12a generates a linearized donor cassette in vivo by both CRISPR-Cas9 and CRISPR-Cas12a, which resulted in increased knock-in efficiency in culture cells. This method also achieved > 25% targeted knock-in of long external DNA (> 4 kb) in mice by both CRISPR-Cas9 and CRISPR-Cas12a. The pCriMGET_9-12a system expands the genomic target space for transgene knock-in and provides a versatile, low-cost, and high-performance CRISPR genome editing tool.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] MicroRNAs tame CRISPR-Cas9
    Jouravleva, Karina
    Zamore, Phillip D.
    NATURE CELL BIOLOGY, 2019, 21 (04) : 416 - 417
  • [32] CRISPR-Cas9 wins Nobel
    Strzyz, Paulina
    NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2020, 21 (12) : 714 - 714
  • [33] The invisible dance of CRISPR-Cas9
    Palermo, Giulia
    Ricci, Clarisse G.
    McCammon, J. Andrew
    PHYSICS TODAY, 2019, 72 (04) : 30 - 36
  • [34] CRISPR-Cas9 in cancer therapeutics
    Randhawa, Shubhchintan
    REPROGRAMMING THE GENOME: CRISPR-CAS-BASED HUMAN DISEASE THERAPY, 2021, 181 : 129 - 163
  • [35] CRISPR-Cas9 Structures and Mechanisms
    Jiang, Fuguo
    Doudna, Jennifer A.
    ANNUAL REVIEW OF BIOPHYSICS, VOL 46, 2017, 46 : 505 - 529
  • [36] Development and application of CRISPR-Cas9 for genome editing
    Zhang, Feng
    TRANSGENIC RESEARCH, 2014, 23 (05) : 842 - 842
  • [37] Allergan dives into CRISPR-Cas9
    不详
    NATURE BIOTECHNOLOGY, 2017, 35 (04) : 296 - 296
  • [38] CRISPR-Cas9 as a Trojan horse
    Monte, Daniel F. M.
    MOLECULAR THERAPY, 2023, 31 (10) : 2817 - 2818
  • [39] CRISPR-Cas9: Advances and Challenges
    Charpentier, E.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 766 - 766
  • [40] CRISPR-Cas9: Power And Challenges
    Charpentier, Emmanuelle
    FASEB JOURNAL, 2016, 30